TCGA-E2-A1IF-01A-11R-A144-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 38
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- MYOGENESIS+0.460
- COAGULATION+0.390
- ANGIOGENESIS+0.380
- P53_PATHWAY+0.340
- APICAL_SURFACE+0.300
- PANCREAS_BETA_CELLS+0.280
- TNFA_SIGNALING_VIA_NFKB+0.280
- NOTCH_SIGNALING+0.270
- KRAS_SIGNALING_UP+0.260
Top 10 suppressed
- MYC_TARGETS_V1-0.490
- PROTEIN_SECRETION-0.490
- G2M_CHECKPOINT-0.480
- E2F_TARGETS-0.440
- INTERFERON_ALPHA_RESPONSE-0.430
- MTORC1_SIGNALING-0.430
- UNFOLDED_PROTEIN_RESPONSE-0.430
- MITOTIC_SPINDLE-0.420
- INTERFERON_GAMMA_RESPONSE-0.370
- ANDROGEN_RESPONSE-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A0CP-01A-11R-A034-07 | — | A | 0.875 |
| 2 | 57583139-d2d3-4b97-a616-aa96058d4682 | — | — | 0.872 |
| 3 | TCGA-A7-A425-01A-11R-A24H-07 | — | A | 0.869 |
| 4 | SRR493947 | — | cohortA1 | 0.863 |
| 5 | d496ef4f-4716-4e6e-94e3-fce93b26d4ee | — | — | 0.853 |
| 6 | TCGA-OL-A66J-01A-11R-A29R-07 | — | A | 0.852 |
| 7 | R236 | — | — | 0.851 |
| 8 | SRR35579814 | — | A | 0.850 |
| 9 | 69d9a82b-5c37-45bd-a1cf-ffe1392e84fc | — | — | 0.848 |
| 10 | SRR5903552 | — | cohortA1 | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| MYOGENESIS | 0.460 | Inavolisib | — uncovered |
| COAGULATION | 0.390 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.340 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.280 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.230 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |